Medicare proposes limited coverage for controversial Alzheimer’s treatment

Published



The Centers for Medicare and Medicaid Services announced that it would only cover the expensive new Alzheimer’s treatment from Biogen for patients enrolled in clinical trials, significantly limiting the patient population that could benefit from it.

“CMS has proposed an evidence-based coverage policy after experts reviewed all relevant publicly available evidence and feedback received from stakeholders,” said CMS Administrator Chiquita Brooks-LaSure.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.